He et al. have shown by extensive application of the UALCAN portal that the methylation level of the promoter of NALCN is significantly higher in the vast majority of cancers, including lung cancer, while it is lower in pheochromocytomas and paragangliomas compared to normal tissues [24]. This evidence concerns the gene NALCN and cancer.